drugset / Trial / NCT02676596

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

NCT02676596 ↗

Phase 1 Completed 120 enrolled Kowa Research Institute, Inc.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to investigate the safety tolerability, and PK profile of K-312 and its metabolites in healthy Japanese and non-Japanese adults.

Timeline

Start
2014-04
Primary completion
2014-11
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject K-312 Unknown 10 mg —
Subject K-312 Unknown 25 mg —
Subject K-312 Unknown 50 mg —
Subject K-312 Unknown 100 mg —
Subject K-312 Unknown 200 mg —
Subject K-312 Unknown 400 mg —

Indications